---
title: "AbbVie is already a dividend king. Here's why the $10.9 billion Apogee deal could make it a dynasty"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292388234.md"
description: "AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak."
datetime: "2026-07-12T01:35:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292388234.md)
  - [en](https://longbridge.com/en/news/292388234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292388234.md)
---

# AbbVie is already a dividend king. Here's why the $10.9 billion Apogee deal could make it a dynasty

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

### Related Stocks

- [APGE.US](https://longbridge.com/en/quote/APGE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie piles on $8 billion in debt for its Apogee deal -- should dividend investors worry?](https://longbridge.com/en/news/295533701.md)
- [Apogee Therapeutics gelar rapat khusus pemegang saham lewat webcast langsung](https://longbridge.com/en/news/295572948.md)
- [Voya Global Equity Dividend and Premium Opportunity Fund declares $0.05 dividend](https://longbridge.com/en/news/296144461.md)
- [Badger Meter raises dividend by 10% to $0.44](https://longbridge.com/en/news/296120783.md)
- [3 magnificent high-yield dividend stocks to buy that are near 52-week lows](https://longbridge.com/en/news/296025716.md)